ESMO 2017 | Evolution, not revolution: the acceptance of biosimilars by practicing clinicians
Mark Pegram, MD, from the Stanford Women’s Cancer Center, Stanford, CA discusses the topic of how practicing clinicians in oncology will accept the introduction of biosimilars into the clinic, talking us through the data they will soon be able to review and how this may affect their judgment. Similar situations have arisen in the past, and Dr Pegram gives us some examples of how clinicians reacted to new agents. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.
Get great new content delivered to your inboxSign up